ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1560

The Effect of Anti Estrogen Therapy (AET) on Rheumatoid Arthritis

Bassam Alhaddad1, Amrita Kaur Bath2, Bassem Zraik3, Mohamed Alalwani4 and Stanley P Ballou1, 1Rheumatology, Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, 2Internal medicine, Fairview Hospital- Cleveland Cinic, Cleveland, OH, 3Internal Medicine, Fairview Hospital- Cleveland Clinic, cleveland, OH, 4Hospital Medicine, Cleveland Clinic, Cleveland, OH

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: cancer and rheumatoid arthritis (RA), Disease Activity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The well-known positive effect of pregnancy on improving Rheumatoid Arthritis (RA) disease activity suggests that hormonal changes may play a role in disease pathogenesis and raises a concern that anti-estrogen therapy (AET) including Aromatase Inhibitors [AI] and selective estrogen receptor modulators [SERMs] may have an adverse effect on RA. AI can cause musculoskeletal symptoms including AI induced arthritis. Recent observations by our group suggest an increased incidence of RA among patients using either AI or SERMs (1). We intended to examine the effect of AET on disease activity in patients with established RA.

Methods: We searched the electronic medical records in 2 medical centers for patients with the diagnoses of both breast cancer and RA.  Of 435 charts reviewed, we identified 40 who had validated RA diagnosis, used SERMs or AI for breast cancer and had appropriate rheumatology evaluation. Data collected included age, BMI, smoking, RA disease duration, clinical status, serology and medication use.  The primary outcome measure was worsening of disease within 6 months of AET initiation compared to the most recent evaluation prior to AET, using 2 visits before and 2 after AET. Worsening was defined as an increase in swollen & tender joint count, patient and/or physician global assessment, or documented flare/worsening by rheumatologist assessment, including the need to discontinue AET or modify RA therapy.  Worsening could not be attributed to changes or discontinuation of RA therapy. We also reviewed patients who developed RA following initiation of AET.

Results: Thirty eight patients were analyzed. Mean age was 59 years and median duration of RA prior to cancer diagnosis was 8.2 years. AETs used included tamoxifen (6), anastrazole (23) and other AI (9). RA clinical status prior to AET initiation was classified as complete remission (25%), stable (55%) and active (20%), 76.7% were seropositive. Seven patients developed new onset seropositive RA with a mean of 12 months (1-24 months) following initiation of AI (5 patients) and tamoxifen (2). RA worsened in 18 out of 31 patients (58%) after initiating AET, primarily after AI (16/18 patients). On comparing patients who worsened to those who did not (table 1), worsening group was significantly more likely to be younger and seropositive, while age and BMI did not differ between groups. Eighty three percent of patients who were not on DMARDs or biologics worsened while the patients who were maintained on biologics did not.

Table 1: Comparison of Patients with and without RA worsening

Worsening

Worsening

Factor

Total

(N=31)

Yes

(N=18)

No

(N=13)

p-value

Disease status

0.61d

.     Remission

8(25.8)

6(33.3)

2(15.4)

.     Stable/Mild

17(54.8)

9(50.0)

8(61.5)

.     Active

6(19.4)

3(16.7)

3(23.1)

smoking

0.48d

  •   yes

10(32.3)

5(27.8)

5(38.5)

  • No 

21(67.7)

13(72.2)

8(61.5)

seropositive

0.025d

.     Yes

23(76.7)

16(94.1)

7(53.8)

.     No

7(23.3)

1(5.9)

6(46.2)

chemotherapy

0.40d

.     Yes

7(24.1)

3(17.6)

4(33.3)

.     No

22(75.9)

14(82.4)

8(66.7)

No RA meds or prednisone only

0.023c

.     RA Meds

19(61.3)

8(44.4)

11(84.6)

.     Prednisone or None

12(38.7)

10(55.6)

2(15.4)

DMARD

0.47c

.     No DMARD

19(61.3)

12(66.7)

7(53.8)

.     DMARD

12(38.7)

6(33.3)

6(46.2)

On biologics

0.023d

.     No Biologics

27(87.1)

18(100.0)

9(69.2)

.     Biologics

4(12.9)

0(0.0)

4(30.8)

Patient Age(Years)

59.2±17.0

54.7±19.0

65.3±11.7

0.085a

Disease duration(Years)

7.1±8.5

7.6±10.2

6.3±4.9

0.71a

BMI

29.6±8.6

28.0±7.1

31.8±10.3

0.23a

Values presented as Mean ± SD, Median [P25, P75], Median (min, max) or N (column %).

p-values: a=ANOVA, b=Kruskal-Wallis test, c=Pearson’s chi-square test, d=Fisher’s Exact test.

Conclusion: Our study includes the largest reported number of new onset RA cases following the initiation of AET, Our data suggest that use of AET may worsen RA in patients with established disease, especially in those who are not on DMARDs or biologic therapy.

References: 1-Chen JY, Ballou SP. The Effect of Antiestrogen Agents on Risk of Autoimmune Disorders in Patients with Breast Cancer. J Rheumatol. 2014 Oct 1


Disclosure: B. Alhaddad, None; A. K. Bath, None; B. Zraik, None; M. Alalwani, None; S. P. Ballou, None.

To cite this abstract in AMA style:

Alhaddad B, Bath AK, Zraik B, Alalwani M, Ballou SP. The Effect of Anti Estrogen Therapy (AET) on Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/the-effect-of-anti-estrogen-therapy-aet-on-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-effect-of-anti-estrogen-therapy-aet-on-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology